Evogene Ltd. EVGN
0.42
0.00
0.00%
as of 25 Sep
- Market cap
- $6.3M
- P/E
- 0.0×
Follow EVGN
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.24 | 4.07 | 2.25 | 4.45 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.72) | (2.54) | (3.22) | (2.98) | |
P/B ratio |
0.93 | 0.94 | 0.72 | 0.58 | |
Price to Tangible BV |
0.00 | 0.00 | 433.07 | 1.88 | |
EV/Sales |
(2.40) | (3.03) | (1.12) | (2.70) | |
EV/EBITDA |
0.37 | 0.54 | 0.37 | 0.61 | |
EV/Operating CF |
0.36 | 0.50 | 0.32 | 0.39 | |
EV/FCF |
0.37 | 0.50 | 0.32 | 0.38 | |
Quick Ratio |
3.54 | 2.76 | 4.32 | 4.41 | |
Current Ratio |
3.57 | 2.79 | 4.54 | 5.11 | |
Net Debt/EBITDA |
3.85 | 10.62 | 2.56 | 7.91 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.07 | 0.07 | 0.13 | 0.07 | |
Operating CF/Net income |
1.12 | 0.50 | 0.51 | (0.86) | |
Capex/Depreciation |
0.61 | 0.01 | 0.07 | 0.03 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
395.97% | 550.60% | 372.74% | 440.71% | |
Selling, General and Administrative Expense of Revenue |
348.13% | 462.57% | 204.37% | 479.17% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
29.39% | (2.69%) | 23.34% | 17.31% | |
Graham Net Nets |
0.59 | 0.67 | 0.87 | 1.21 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(206.82%) | (180.52%) | (106.36%) | (43.86%) | |
Free Cash Flow Yield |
(200.84%) | (149.22%) | (156.55%) | (158.98%) | |
Revenue per Share |
0.03 | 0.03 | 0.08 | 0.04 | |
Operating CF per Share |
(0.16) | (0.30) | (0.34) | (0.38) | |
Capex per Share |
0.01 | 0.00 | 0.01 | 0.00 | |
Free Cash Flow per Share |
(0.16) | (0.30) | (0.34) | (0.38) | |
Cash per Share |
0.77 | 1.34 | 1.65 | 1.83 | |
Shareholders Equity per Share |
0.47 | 0.82 | 1.52 | 1.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.47 | 0.82 | 1.52 | 1.98 | |
Free Cash Flow |
(1.89) | (2.93) | (2.64) | (3.31) | |
Working Capital |
7.81 | 9.60 | 12.19 | 16.76 | |
Capital Expenditures |
0.08 | 0.02 | 0.04 | 0.02 | |
Net Current Asset Value |
3.18 | 5.01 | 7.56 | 12.00 | |
EV/EBIT |
0.28 | 0.39 | 0.31 | 0.48 | |
Capex to Sales |
(0.23) | (0.06) | (0.06) | (0.08) | |
Net Profit Margin |
(509.51%) | (1,757.49%) | (799.70%) | 1,241.67% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.60 | 2.50 | 2.52 | 2.97 | |
Average Payables |
0.48 | 0.53 | 0.93 | 0.83 | |
Average Inventory |
1.02 | 1.16 | 1.01 | 1.78 | |
Average Assets |
23.68 | 26.13 | 29.96 | 33.10 | |
Average Common Equity |
9.07 | 10.19 | 13.41 | 14.75 |
Columns are period end dates